Lyra Therapeutics’ bioresorbable treatments
Watertown, Mass.-based Lyra Therapeutics is looking to make waves in the ear, nose and throat (otolaryngology) disease treatment space with drugs administered through a bioresorbable polymeric matrix.
LYR-210, the company’s therapeutic, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages to treat chronic rhinosinusitis (CRS) in those who have not undergone surgery for the disease.
The therapeutic is under development for CRS patients, while Lyra’s XTreo platform is being developed to address other disease areas through precise, consistent and local delivery combined in a single administration.
Comprising XTreo is a biocompatible mesh scaffold to maximize surface area for drug release while maintaining underlying tissue function, as well as an engineered elastomeric matrix to dynamically adapt to target anatomy and a versatile polymer-drug complex to enable tunable drug elution for long-term dosing.
In December 2020, Lyra announced positive topline results for its LANTERN Phase 2 study of LYR-210 for the treatment of CRS, including statistically significant improvement in a composite score of the four cardinal symptoms of CRS compared to control.